Approval · Notice of Compliance 5907 · 2004
PHL-RANITIDINE: Notice of Compliance 5907
Issued November 17, 2004
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 5907
- Date
- November 17, 2004
- Company
- Pharmel Inc.Montreal, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Admin
- Reason
- Product name change form riva-ranitidine
- Therapeutic class
- Histamine H2-receptor antagonist
- Canadian reference product
- ZANTAC (Glaxo Wellcome Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PHL-RANITIDINE | 02245782 | Cancelled Post Market |
| PHL-RANITIDINE | 02245783 | Cancelled Post Market |
Medicinal ingredients
- RANITIDINE HCL 150 MG per TAB
- RANITIDINE HCL 300 MG per TAB